Albany Molecular Research Inc (AMRI.O) People | Reuters.com
Edition:
United States

Albany Molecular Research Inc (AMRI.O)

AMRI.O on Nasdaq

13.51USD
24 Jun 2016
Change (% chg)

$-0.48 (-3.43%)
Prev Close
$13.99
Open
$13.38
Day's High
$13.79
Day's Low
$13.38
Volume
685,540
Avg. Vol
311,292
52-wk High
$22.48
52-wk Low
$12.45

Summary

Name Age Since Current Position

Thomas D' Ambra

59 2013 Non-Executive Chairman of the Board

William Marth

60 2014 President, Chief Executive Officer, Director

Felicia Ladin

43 2015 Chief Financial Officer, Senior Vice President, Treasurer

Lori Henderson

53 2011 Senior Vice President, General Counsel, Secretary

Christopher Conway

2015 Senior Vice President - Discovery and Development and Global Commercial Sales

Milton Boyer

2015 Senior Vice President - Drug Product Manufacturing

Steven Hagen

54 2012 Senior Vice President - Manufacturing and Pharmaceuticals

George Svokos

57 2015 Chief Commercial Officer and Senior Vice President, API

Jimmy Wang

2015 Chief Information Officer

Una Ryan

73 2010 Lead Independent Director

David Deming

62 2016 Director

Gerardo Gutierrez

2015 Director

Kenneth Hagen

2016 Director

Anthony Maddaluna

63 2016 Director

Kevin O' Connor

60 2000 Independent Director

Arthur Roth

75 2003 Independent Director

Biographies

Name Description

Thomas D' Ambra

Dr. Thomas E. D' Ambra, Ph.D., is Non-Executive Chairman of the Board of Albany Molecular Research Inc., since December 31, 2013. He co-founded the Company in 1991 and served as President and Chief Executive Officer until his retirement in 2013. As of January 2014, Dr. D’Ambra resumed the role of Chairman of the Board of Directors and currently serves in that capacity. During his tenure as an employee of the Company, Dr. D'Ambra had been involved and taken an active role in all aspects of the Company’s business at various times, from bench research scientist to business development, to operational and strategic management and led the Company in its global growth through 2013. He has authored numerous publications and is inventor on over 30 U.S. patents. In August 2014, Dr. D'Ambra was appointed to the Albany College of Pharmacy and Health Sciences' (ACPHS) Board of Trustees and in October 2014 was appointed to the Albany Palace Theater and Performance Arts Center Board of Trustees. He has and continues to serve as an advisor and mentor for new and young companies. Prior to co-founding the Company, Dr. D’Ambra served as the Vice President, Chemistry and co-founder of Coromed, Inc., a traditional development contract research organization, from 1989 to 1991 and Group Leader and Senior Research Chemist with Sterling Winthrop, Inc., a pharmaceutical company, from 1982 to 1989. Dr. D’Ambra holds a B.A. in chemistry from the College of the Holy Cross and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology

William Marth

Mr. William S. Marth is President, Chief Executive Officer, Director of Albany Molecular Research, Inc., since January 1, 2014. Mr. Marth joined AMRI as a member of the Board of Directors in June 2012. Mr. Marth was formerly President and Chief Executive Officer of Teva Americas, retiring from Teva in 2012. He serves as a senior advisor to Teva through the end of 2013. He had previously served as President and Chief Executive Officer of Teva North America from January 2008 to June 2010 and prior to that as President and Chief Executive Officer of Teva USA. He was previously Executive Vice President and Vice President of Sales and Marketing for Teva USA. Mr. Marth earned his B.Sc. in Pharmacy from the University of Illinois in 1977 and his M.B.A. in 1989 from the Keller Graduate School of Management, DeVry University. He is a licensed pharmacist and serves on various other boards and committees, including The University of the Sciences in Philadelphia and the Board of Ambassadors for John Hopkins’ Project RESTORE. In addition, Mr. Marth served as the Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2008 and 2009 and the American Society for Health-System Pharmacists (ASHP) in 2010.

Felicia Ladin

Ms. Felicia Ladin is Chief Financial Officer, Senior Vice President, Treasurer of Albany Molecular Research Inc., since February 4, 2015. Ms. Ladin brings more than 20 years of finance, accounting and tax management experience to AMRI. A CPA by training, Ms. Ladin has spent the majority of her career in the pharmaceutical industry, most recently as Senior Vice President, CFO, Global Specialty Medicines at Teva Pharmaceuticals Industries, Ltd. Between 2008 and 2014, Ms. Ladin held positions of increasing responsibility directing Teva’s financial planning and analysis operations, and from 2002 to 2008 was tax director for the U.S. During her 12 year tenure at Teva, Ms. Ladin was instrumental in developing and implementing financial systems and infrastructure through a number of acquisitions, and driving consistency and efficiencies across locations, supporting the Specialty Medicine division’s growth into an $8 billion global business. Ms. Ladin holds a B.S. in Accounting from the University of Delaware and an M.S. in Taxation from Seton Hall University.

Lori Henderson

Ms. Lori M. Henderson, Esq. is Senior Vice President, General Counsel, Secretary of Albany Molecular Research Inc. Ms. Henderson is responsible for leading all of AMRI’s legal and business development activities for the Company’s locations worldwide, including the United States, Europe and Asia. From 2008 to 2010, she served as General Counsel, Corporate Secretary and Chief Administrative Officer for Rand Worldwide, Inc. where she oversaw the legal, human resource and IT departments of this technology company. From 1999 through 2008 she held increasing positions of responsibility and served as General Counsel, Corporate Secretary and Chief Administrative Officer for Moldflow Corporation, a company operating in the CAD/CAE business with global operations. At Moldflow, Ms. Henderson was responsible for the legal, human resources and IT functions at the Company, and was part of the management team that completed the successful sale of Moldflow to Autodesk in June 2008. Ms. Henderson also served as Corporate Counsel and Secretary at C.P. Clare Corporation and prior to that was an associate at Goodwin Procter LLP, specializing in corporate transactions. Ms. Henderson holds a B.A. from Gordon College and a J.D. from George Washington University.

Christopher Conway

Mr. Christopher Conway is Senior Vice President - Discovery and Development and Global Commercial Sales of Albany Molecular Research Inc. He was Senior Vice President - Global Sales and Marketing of the Company. He is responsible for all global sales, marketing and customer operations functions. Mr. Conway, who joined AMRI in 2008, was most recently Vice President of Global Sales and Marketing. Before joining AMRI, Mr. Conway held sales and leadership positions of increasing responsibility at Johnson and Johnson .

Milton Boyer

Mr. Milton Boyer is Senior Vice President - Drug Product Manufacturing of the Company. He was Vice President of Parenterals. Mr. Boyer's expertise from OsoBio will be applied across all phases of Drug Product, which spans from Pre-Formulation and Formulation Development all the way through to Late Phase and Commercial Parenteral Manufacturing.

Steven Hagen

Dr. Steven R. Hagen, Ph.D., is Senior Vice President - Manufacturing and Pharmaceuticals of Albany Molecular Research Inc., since 22 October 2012. Dr. Hagen joined AMRI in 2005 as senior director of analytical quality services and has risen to positions of increasing responsibility. In 2006, Dr. Hagen was promoted to vice president for quality and analytical chemistry and was responsible for Analytical Chemistry, Quality Assurance and Regulatory Affairs for all AMRI locations. In 2008, Dr. Hagen was promoted to vice president of pharmaceutical development and manufacturing. Prior to AMRI, he spent more than 10 years at Pfizer in positions of increasing responsibility culminating in director of analytical research and development at Pfizer's Global Research and Development Division. Before Pfizer, he managed the analytical activities at Ribi ImmunoChem Research, Inc. in support of R&D, production and quality control. Dr. Hagen earned a Ph.D. in biochemistry and a Master's degree in botany, both from the University of Idaho, as well as a B.A. in biology from Lawrence University.

George Svokos

Mr. George Svokos is Chief Commercial Officer and Senior Vice President, API of Albany Molecular Research Inc., since February 2015. Previously Mr. Svokos had served as our Senior Vice President Sales and General Manager API since January 2014. Prior to joining the Company, Mr. Svokos had been with Teva Pharmaceuticals Industries Ltd. for over 30 years and most recently, he was Senior Vice President of Product and Portfolio Selection, and Business Development, responsible for strategic planning, portfolio selection, new product introductions and business development. From 2011 to 2012, Mr. Svokos was Senior Vice President, US Technical Operations, responsible for strategic planning, manufacturing, supply chain, regulatory and legal compliance, and safety, for eleven U.S. dosage form manufacturing facilities, as well as supply of branded and generic products to the U.S. market from overseas plants in Europe, the Middle East, China and India. Before this role, he served as Executive Vice President of Commercial Operations, Teva API, leading the global sales and marketing of Teva’s API division, including a global sales force, with multibillion-dollar sales. Mr. Svokos is the President of the Drug, Chemical & Associated Technologies Association (DCAT). Mr. Svokos earned an M.B.A. from the University of Missouri and a B.S. in Chemical Engineering from Columbia University.

Jimmy Wang

Dr. Jimmy Wang , Ph.D., is Chief Information Officer of the Company. Dr. Wang brings 25 years of experience managing and deploying technology innovations to various technology, telecommunications and global pharmaceutical companies. Most recently he served as Senior Vice President and Chief Information Officer at OPKO Health Inc., where he established the company's global IT governance process and transformed IT into a centralized delivery organization. Before OPKO Health, Dr. Wang was Senior Vice President and Chief Information Officer at Vertex Pharmaceuticals Inc., where he played a major role in managing implementation, consolidation, and support of Enterprise Operations Support Systems, as well as led the area of scientific computing to use technology to support the area of Innovation and Research. Before Vertex, Dr. Wang was at Teva Pharmaceuticals-America, where he was Vice President and Chief Information Officer. Dr. Wang received his Ph.D. in Operations Research from Southern Methodist University in 1990.

Una Ryan

Dr. Una S. Ryan Ph.D., OBE, is the Lead Independent Director of Albany Molecular Research Inc., since October 2006. She is currently President of Diagnostics for All, a non-profit focused on low-cost and easy-to-use diagnostics for the developing world. Previously, she was President and CEO of Waltham Technologies, Inc. a company in the Clean Water-Clean Energy business. Concurrently, she holds the position of research professor of medicine at Boston University School of Medicine. Prior to joining Waltham, she was President and CEO of AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) and also a member of its Board of Directors, 1993 to 2007. Prior to AVANT, she was director of Health Sciences at Monsanto Company, 1990 to 1993. Before that, she held a number of positions in academia, including research professor of surgery at Washington University School of Medicine in St. Louis, 1990 to 1994; and professor of medicine at the University of Miami School of Medicine, 1972 to 1989. Dr. Ryan graduated from England’s Bristol University, with B.Sc. degrees in Zoology, Chemistry, and Microbiology. In 2009 she received an Honorary D.Sc. from Bristol University. She received a Ph.D. from Cambridge University. Dr. Ryan has served on several private company boards and industry trade organizations, including the board of BIO, and is past chair of the Massachusetts Biotechnology Council. In 2002, she was awarded the Order of the British Empire (O.B.E.) for her work to foster and promote biotechnology.

David Deming

Mr. David H. Deming is Director of the Company. He was Managing Partner, TAG Healthcare Advisors, Mr. Deming founded TAG Healthcare Advisors in 2014. Prior to that, Mr. Deming was Principal at Deming & Co., LLC from September 2012 to March 2013, and CEO of Dimensional SmartNest LLC, a customized retirement solution which Mr. Deming developed and successfully sold to Dimensional Fund Advisors. Previously, Mr. Deming spent over 27 years at JP Morgan Chase and JP Morgan, where he led the healthcare investment banking group for twelve years. He has over 35 years of experience in investment banking, and has focused on the healthcare industry for over 15 years. Mr. Deming’s board positions also include IRX Therapeutics Inc. and Sorrento Therapeutics Inc. He has served as a non-executive Chairman for IRX Therapeutics, a clinical-stage bioresearch company, since May 2014, and as a Director for Sorrento Therapeutics, an antibody-centric, clinical stage biopharmaceutical company, since April 2015. Mr. Deming graduated from Hobart College with a BA in Economics with Highest Honors, where he served as Chair of the Board of Trustees from 2006 to 2012.

Gerardo Gutierrez

Mr. Gerardo Gutierrez is an Director of the Company. Mr. Gutierrez founded Gadea in 1991 and served as its President and Chief Executive Officer. Mr. Gutierrez graduated from the Complutense University of Madrid with a degree in chemistry and obtained a master’s degree in Management Production, Operations and Technology from ICADE Business School.

Kenneth Hagen

Mr. Kenneth P. Hagen, CPA, has been appointed as Director of the Company., effective May 2016. Mr. Hagen joined Pricewaterhouse Coopers in 1975 and became a tax partner in 1986, serving a wide range of pharmaceutical, industrial and technology clients. Since 2000 and until his retirement in 2011, Ken was the Partner-in-Charge of PwC’s Mergers and Acquisition tax practice in Philadelphia. In addition, Ken served as principal tax advisor for over a decade to one of the world’s leaders in generic pharmaceuticals. He also advised other clients on tax issues associated with large and diverse corporate transactions. Mr. Hagen is a CPA and holds a BS in Accounting from Pennsylvania State University and a Masters in Taxation from Villanova University.

Anthony Maddaluna

Mr. Anthony J. Maddaluna is Director of the Company. Tony’s career with Pfizer spans more than 40 years. He joined Pfizer in 1975 in St. Louis, Missouri, serving in the Minerals, Pigments and Metals (MPM) division in several positions, including Production Supervisor. From 1978 to 1983, he held various engineering positions in the Adams, Massachusetts, MPM division and subsequently worked in the Pharmaceutical division as Manager, Technical Training. In 1985, Tony relocated to Terre Haute, Indiana, where he held various positions before becoming Plant Manager. In 1994, he moved to Pfizer's Barceloneta, Puerto Rico plant as General Manager. He was named Vice President/Team Leader, Europe in 1998 and also had responsibility for Global Logistics, Global Operations Team and Strategic Planning during a portion of this time. He was named Vice President, Strategy & Supply Network Transformation in 2008, and Senior Vice President in 2009. Tony was named to his current position at Pfizer in 2011. Before joining Pfizer, Tony worked at the U.S. Environmental Protection Agency and at Johnson & Johnson as an engineer. Tony represents Pfizer on the National Association of Manufacturers (NAM) and is a member of the NAM Executive Committee. Tony holds a B.S. in Chemical Engineering from Northeastern University and an M.B.A. in Management and Organization Development from Southern Illinois University.

Kevin O' Connor

Mr. Kevin O' Connor is Independent Director of Albany Molecular Research Inc., since March 2000. Mr. O’Connor has served as Chief Executive Officer of Tech Valley Communications, a telecommunications company, since July 2000. Mr. O’Connor previously served as the President of the Center for Economic Growth, Inc., a business-sponsored economic development organization, from February 1992 through July 2000. Mr. O’Connor also served as a Deputy Commissioner for the New York State Department of Economic Development from September 1987 to February 1992, as a Program Associate for the New York State Governor’s Office from July 1984 to September 1987 and held various positions in the New York State Division of the Budget and the New York State Department of Health from January 1980 to July 1984. Mr. O’Connor also serves as a director of several private companies and non-profit organizations. Mr. O’Connor holds a B.A. degree in history and a Masters degree in public administration from the State University of New York College in Brockport.

Arthur Roth

Mr. Arthur J. Roth, CPA, is Independent Director of Albany Molecular Research Inc., since October 2003. Mr. Roth previously served as commissioner of the New York State Department of Taxation and Finance from 1999 to 2003. Prior to his appointment as Commissioner, Mr. Roth was Deputy Commissioner for Operations, New York State Department of Taxation and Finance from 1996 until 1999. Mr. Roth was a senior consulting director with Coopers and Lybrand from 1992 to 1996 and a founder and managing director of Roth Nobis & Company, an accounting firm serving the manufacturing and service industries, from 1968 to 1992. Mr. Roth serves as a director for MVP Healthcare and also serves as director for several non-profit companies. Mr. Roth served on the Board of Directors and as the Chair of the Audit Committee of First Albany Capital Inc. from October 2003 until August 2006. Mr. Roth is a certified public accountant and holds a B.A. degree from Syracuse University.